Erythropoietin in cancer patients: pros and cons
PURPOSE OF REVIEWAnaemia is a frequent complication of cancer. Recently, some concerns have appeared regarding the safety of erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia in cancer patients. The current review will analyse the main arguments in favour of erythropoietin (EPO),...
Gespeichert in:
| Veröffentlicht in: | Current opinion in oncology 2010-07, Vol.22 (4), p.307-311 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 311 |
|---|---|
| container_issue | 4 |
| container_start_page | 307 |
| container_title | Current opinion in oncology |
| container_volume | 22 |
| creator | Dicato, Mario Plawny, Laurent |
| description | PURPOSE OF REVIEWAnaemia is a frequent complication of cancer. Recently, some concerns have appeared regarding the safety of erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia in cancer patients. The current review will analyse the main arguments in favour of erythropoietin (EPO), as well as those against EPO in chemotherapy-induced anaemia and in cancer-related anaemia. The principal concerns are tumour progression, increased mortality and the risk of venous thromboembolic events (VTEs). Recent meta-analyses have come to divergent conclusions.
RECENT FINDINGSSeveral meta-analyses have reviewed the data regarding VTEs, EPO receptors on tumours and tumour progression as well as mortality.
SUMMARYAs of now, ESAs should only be used within the indications as given in the various guidelines. |
| doi_str_mv | 10.1097/CCO.0b013e32833aa9de |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733260932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733260932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421e-93eb6fb5bfaaabf1e92abb4148d515229b342c2c82e10aeb739bc536914ef7883</originalsourceid><addsrcrecordid>eNp9kM1Lw0AQxRdRbK3-ByK5eYrOfiTZ9SalfkChFwVvy-5mQqNpEncTSv97V1o9eBAGZg6_997wCLmkcENBFbfz-eoGLFCOnEnOjVElHpEpzThNC-Bvx_EGAaksRD4hZyG8A1CmQJ2SCQOhZKbklMDC74a17_quxqFukzjOtA590puhxnYId0nvu5CYtkxc14ZzclKZJuDFYc_I68PiZf6ULlePz_P7ZeoEo5gqjjavbGYrY4ytKCpmrBVUyDKjGWPKcsEcc5IhBYO24Mq6jOeKCqwKKfmMXO99Y_rniGHQmzo4bBrTYjcGXXDOclCcRVLsSRf_DB4r3ft6Y_xOU9DfVelYlf5bVZRdHQJGu8HyV_TTTQTkHth2zYA-fDTjFr1eo2mG9f_eX04aeE0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733260932</pqid></control><display><type>article</type><title>Erythropoietin in cancer patients: pros and cons</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Dicato, Mario ; Plawny, Laurent</creator><creatorcontrib>Dicato, Mario ; Plawny, Laurent</creatorcontrib><description>PURPOSE OF REVIEWAnaemia is a frequent complication of cancer. Recently, some concerns have appeared regarding the safety of erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia in cancer patients. The current review will analyse the main arguments in favour of erythropoietin (EPO), as well as those against EPO in chemotherapy-induced anaemia and in cancer-related anaemia. The principal concerns are tumour progression, increased mortality and the risk of venous thromboembolic events (VTEs). Recent meta-analyses have come to divergent conclusions.
RECENT FINDINGSSeveral meta-analyses have reviewed the data regarding VTEs, EPO receptors on tumours and tumour progression as well as mortality.
SUMMARYAs of now, ESAs should only be used within the indications as given in the various guidelines.</description><identifier>ISSN: 1040-8746</identifier><identifier>EISSN: 1531-703X</identifier><identifier>DOI: 10.1097/CCO.0b013e32833aa9de</identifier><identifier>PMID: 20498598</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins, Inc</publisher><subject>Anemia - complications ; Anemia - drug therapy ; Anemia - metabolism ; Disease Progression ; Erythropoietin - metabolism ; Hematinics - adverse effects ; Hematinics - therapeutic use ; Humans ; Hypertension - chemically induced ; Neoplasms - complications ; Neoplasms - pathology ; Red-Cell Aplasia, Pure - chemically induced ; Risk Assessment ; Seizures - chemically induced</subject><ispartof>Current opinion in oncology, 2010-07, Vol.22 (4), p.307-311</ispartof><rights>2010 Lippincott Williams & Wilkins, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421e-93eb6fb5bfaaabf1e92abb4148d515229b342c2c82e10aeb739bc536914ef7883</citedby><cites>FETCH-LOGICAL-c421e-93eb6fb5bfaaabf1e92abb4148d515229b342c2c82e10aeb739bc536914ef7883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20498598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dicato, Mario</creatorcontrib><creatorcontrib>Plawny, Laurent</creatorcontrib><title>Erythropoietin in cancer patients: pros and cons</title><title>Current opinion in oncology</title><addtitle>Curr Opin Oncol</addtitle><description>PURPOSE OF REVIEWAnaemia is a frequent complication of cancer. Recently, some concerns have appeared regarding the safety of erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia in cancer patients. The current review will analyse the main arguments in favour of erythropoietin (EPO), as well as those against EPO in chemotherapy-induced anaemia and in cancer-related anaemia. The principal concerns are tumour progression, increased mortality and the risk of venous thromboembolic events (VTEs). Recent meta-analyses have come to divergent conclusions.
RECENT FINDINGSSeveral meta-analyses have reviewed the data regarding VTEs, EPO receptors on tumours and tumour progression as well as mortality.
SUMMARYAs of now, ESAs should only be used within the indications as given in the various guidelines.</description><subject>Anemia - complications</subject><subject>Anemia - drug therapy</subject><subject>Anemia - metabolism</subject><subject>Disease Progression</subject><subject>Erythropoietin - metabolism</subject><subject>Hematinics - adverse effects</subject><subject>Hematinics - therapeutic use</subject><subject>Humans</subject><subject>Hypertension - chemically induced</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - pathology</subject><subject>Red-Cell Aplasia, Pure - chemically induced</subject><subject>Risk Assessment</subject><subject>Seizures - chemically induced</subject><issn>1040-8746</issn><issn>1531-703X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1Lw0AQxRdRbK3-ByK5eYrOfiTZ9SalfkChFwVvy-5mQqNpEncTSv97V1o9eBAGZg6_997wCLmkcENBFbfz-eoGLFCOnEnOjVElHpEpzThNC-Bvx_EGAaksRD4hZyG8A1CmQJ2SCQOhZKbklMDC74a17_quxqFukzjOtA590puhxnYId0nvu5CYtkxc14ZzclKZJuDFYc_I68PiZf6ULlePz_P7ZeoEo5gqjjavbGYrY4ytKCpmrBVUyDKjGWPKcsEcc5IhBYO24Mq6jOeKCqwKKfmMXO99Y_rniGHQmzo4bBrTYjcGXXDOclCcRVLsSRf_DB4r3ft6Y_xOU9DfVelYlf5bVZRdHQJGu8HyV_TTTQTkHth2zYA-fDTjFr1eo2mG9f_eX04aeE0</recordid><startdate>201007</startdate><enddate>201007</enddate><creator>Dicato, Mario</creator><creator>Plawny, Laurent</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201007</creationdate><title>Erythropoietin in cancer patients: pros and cons</title><author>Dicato, Mario ; Plawny, Laurent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421e-93eb6fb5bfaaabf1e92abb4148d515229b342c2c82e10aeb739bc536914ef7883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Anemia - complications</topic><topic>Anemia - drug therapy</topic><topic>Anemia - metabolism</topic><topic>Disease Progression</topic><topic>Erythropoietin - metabolism</topic><topic>Hematinics - adverse effects</topic><topic>Hematinics - therapeutic use</topic><topic>Humans</topic><topic>Hypertension - chemically induced</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - pathology</topic><topic>Red-Cell Aplasia, Pure - chemically induced</topic><topic>Risk Assessment</topic><topic>Seizures - chemically induced</topic><toplevel>online_resources</toplevel><creatorcontrib>Dicato, Mario</creatorcontrib><creatorcontrib>Plawny, Laurent</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dicato, Mario</au><au>Plawny, Laurent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erythropoietin in cancer patients: pros and cons</atitle><jtitle>Current opinion in oncology</jtitle><addtitle>Curr Opin Oncol</addtitle><date>2010-07</date><risdate>2010</risdate><volume>22</volume><issue>4</issue><spage>307</spage><epage>311</epage><pages>307-311</pages><issn>1040-8746</issn><eissn>1531-703X</eissn><abstract>PURPOSE OF REVIEWAnaemia is a frequent complication of cancer. Recently, some concerns have appeared regarding the safety of erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia in cancer patients. The current review will analyse the main arguments in favour of erythropoietin (EPO), as well as those against EPO in chemotherapy-induced anaemia and in cancer-related anaemia. The principal concerns are tumour progression, increased mortality and the risk of venous thromboembolic events (VTEs). Recent meta-analyses have come to divergent conclusions.
RECENT FINDINGSSeveral meta-analyses have reviewed the data regarding VTEs, EPO receptors on tumours and tumour progression as well as mortality.
SUMMARYAs of now, ESAs should only be used within the indications as given in the various guidelines.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>20498598</pmid><doi>10.1097/CCO.0b013e32833aa9de</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8746 |
| ispartof | Current opinion in oncology, 2010-07, Vol.22 (4), p.307-311 |
| issn | 1040-8746 1531-703X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733260932 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Anemia - complications Anemia - drug therapy Anemia - metabolism Disease Progression Erythropoietin - metabolism Hematinics - adverse effects Hematinics - therapeutic use Humans Hypertension - chemically induced Neoplasms - complications Neoplasms - pathology Red-Cell Aplasia, Pure - chemically induced Risk Assessment Seizures - chemically induced |
| title | Erythropoietin in cancer patients: pros and cons |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T01%3A06%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erythropoietin%20in%20cancer%20patients:%20pros%20and%20cons&rft.jtitle=Current%20opinion%20in%20oncology&rft.au=Dicato,%20Mario&rft.date=2010-07&rft.volume=22&rft.issue=4&rft.spage=307&rft.epage=311&rft.pages=307-311&rft.issn=1040-8746&rft.eissn=1531-703X&rft_id=info:doi/10.1097/CCO.0b013e32833aa9de&rft_dat=%3Cproquest_cross%3E733260932%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733260932&rft_id=info:pmid/20498598&rfr_iscdi=true |